|
Emerging markets and new applications
In the U.S., one million people undergo percutaneous treatment for coronary disease each year. That keeps AngioJet catheters in high demand among interventional cardiologists. Our coronary catheter line, including the soon-to-be released Spiroflex™-VG catheter, also holds promise for the treatment of blocked saphenous vein grafts (SVG), the large leg veins routinely used in coronary bypass surgeries.
What’s the next technology leap at Possis? Our next-generation drive unit: the AngioJet Ultra Console, planned for launch in 2006. This transformative new technology platform will make AngioJet thrombectomy procedures much faster and easier to set-up and
operate – a major advantage for hospital staff in emergency procedures.
New therapy needs are emerging too, especially in the peripheral vascular market. Each year, 600,000 people are diagnosed with deep vein thrombosis (DVT) – blood clots in the deep veins of the legs. Of those, 200,000 develop pulmonary embolism (PE) – a
potentially fatal clot in the vessels that serve the lungs.
Possis has the financial strength, medical industry experience and technology to develop products and seek indications for therapies that address DVT, PE,
and other growing disease states.
|
|
Funding more trials
Today, Possis is sponsoring more key patient registries, investigational clinical studies, and after-market studies than ever before. We’re also funding an ongoing program for physician-sponsored clinical research. Enrollment for JetStent, an important, international multicenter trial now underway, will help document the effectiveness of AngioJet thrombectomy in high-risk cardiac patients. Other investigational studies will evaluate the role of AngioJet thrombectomy in the treatment of deep vein thrombosis. Many more studies are planned or underway.
Gaining ground:
combination therapies
We’re working closely with many physicians now using combination drug/device therapies as part of their interventional treatments. Our new Power Pulse delivery system incorporates combination therapy that capitalizes on this practice trend, allowing physicians
to directly infuse medication into a difficult thrombus before
evacuating it with the AngioJet Xpeedior® catheter.
Also, we plan to introduce the GuardDOG® temporary occlusion system in 2006. The GuardDOG system allows physicians to quickly and effectively manage blood flow during interventions. This may be particularly valuable when combined with AngioJet thrombectomy and Power Pulse delivery.
|
